ストックスクリーナーアプリを入手
11.34
9.50%
-1.1862
前日終値:
$12.53
開ける：
$12.54
24時間の取引高:
1.57M
Relative Volume:
0.93
時価総額：
$1.27B
収益：
$577.74M
当期純損益:
$-149.78M
株価収益率:
-8.1027
EPS:
-1.4
ネットキャッシュフロー:
$-78.21M
1週間 パフォーマンス:
+11.83%
1か月 パフォーマンス:
-16.92%
6か月 パフォーマンス:
-2.41%
1年 パフォーマンス:
-47.77%
1日の値動き範囲:
$11.31
$12.99
1週間の範囲:
$9.82
$14.97
52週間の値動き範囲:
$9.82
$22.95
Novocure Ltd Stock (NVCR) Company Profile
Compare NVCR vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
11.34 | 1.40B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
112.32 | 193.83B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
372.78 | 140.01B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
101.11 | 129.33B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
75.80 | 109.92B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
77.01 | 44.36B | 6.07B | 1.06B | 799.60M | 1.8527 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | 開始されました | Ladenburg Thalmann | Buy |
| 2024-12-02 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-10-16 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-08-28 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | 開始されました | SVB Securities | Outperform |
| 2023-07-31 | アップグレード | Evercore ISI | Underperform → In-line |
| 2023-06-07 | アップグレード | Wedbush | Underperform → Neutral |
| 2023-05-16 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-01-06 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2022-11-29 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2022-05-16 | 開始されました | H.C. Wainwright | Buy |
| 2022-02-08 | 開始されました | Loop Capital | Buy |
| 2022-02-02 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-01-20 | アップグレード | Truist | Hold → Buy |
| 2022-01-03 | アップグレード | Evercore ISI | Underperform → In-line |
| 2021-07-01 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-14 | ダウングレード | Wedbush | Neutral → Underperform |
| 2021-01-25 | 繰り返されました | Piper Sandler | Overweight |
| 2020-09-23 | 開始されました | Northland Capital | Outperform |
| 2020-09-18 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | ダウングレード | Truist | Buy → Hold |
| 2020-06-01 | 再開されました | Oppenheimer | Perform |
| 2020-05-01 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-04-09 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2020-03-05 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-07-29 | アップグレード | SunTrust | Hold → Buy |
| 2019-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-07-26 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-03-20 | 開始されました | SunTrust | Hold |
| 2018-11-02 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | 開始されました | Evercore ISI | Outperform |
| 2018-04-18 | 繰り返されました | Mizuho | Buy |
| 2018-02-23 | 繰り返されました | Mizuho | Buy |
| 2017-05-24 | アップグレード | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | 繰り返されました | Wedbush | Outperform |
| 2016-01-19 | 開始されました | Barclays | Underweight |
| 2015-12-02 | 開始されました | Deutsche Bank | Hold |
すべてを表示
Novocure Ltd (NVCR) 最新ニュース
Novocure wins FDA approval to treat pancreatic cancer with electric fields - MedTech Dive
NovoCure (NVCR) Stock Surges on Pancreatic Cancer Treatment Approval - Blockonomi
Novocure’s stock rises 37% on FDA clearance of pancreatic cancer treatment device - Yahoo Finance
Soleus Adds a Significant Number of Celcuity Shares - The Motley Fool
NovoCure (NVCR) Stock Soars Following Pancreatic Cancer Treatment Approval - CoinCentral
NovoCure (NVCR) stock is trending overnight — here's what you should know - MSN
NovoCure (NASDAQ:NVCR) Shares Gap UpTime to Buy? - MarketBeat
Assessing NovoCure (NVCR) Valuation After FDA Approval Of Optune Pax For Pancreatic Cancer - Yahoo Finance
Approval for pancreatic cancer treatment boosts NovocureGlobes - Globes - Israel Business News
HC Wainwright & Co. Raises NovoCure (NVCR) Price Target to $47 | - GuruFocus
NovoCure Stock Surges After FDA Approves Optune Pax - Benzinga
Novocure Wins FDA Nod for Optune Pax Pancreatic Cancer Treatment - Medical Product Outsourcing
Stock Market Today: Dow Jones, S&P 500 Futures Gain After Strong Jobs Report—Micron, Novocure, Fastly In Focus (UPDATED) - Benzinga
NovoCure stock price target raised to $47 from $39 at H.C. Wainwright By Investing.com - Investing.com India
NovoCure stock price target raised to $47 from $39 at H.C. Wainwright - Investing.com
NovoCure Limited's (NASDAQ:NVCR) 26% Dip In Price Shows Sentiment Is Matching Revenues - simplywall.st
Novocure (NVCR) Shares Surge on FDA Approval for Optune Pax - GuruFocus
U.S. Stock Futures Rise as Fastly and Novocure Surge - Intellectia AI
Novocure shares surge after FDA approves pancreatic cancer device By Investing.com - Investing.com South Africa
Novocure shares surge after FDA approves pancreatic cancer device - Investing.com India
Form 8-KMaterial Events - Stock Titan
First new pancreatic cancer treatment in nearly 30 years is wearable - Stock Titan
Novocure shares soar 30% after FDA nod for pancreatic cancer device - Investing.com Australia
FDA Approves Novocure's Optune Pax for Pancreatic Cancer Treatme - GuruFocus
NovoCure Ltd treatment gains FDA approval for pancreatic cancer - Traders Union
Novocure Ltd FDA Approval of Optune Pax for Pancreatic Cancer - TradingView
FDA clears Novocure (NVCR) Optune Pax for locally advanced pancreatic cancer - Stock Titan
NovoCure (NVCR) Stock Is Trending OvernightHere's What You Should Know - Bitget
Assessing NovoCure (NVCR) Valuation After Prolonged Share Price Weakness In Tumor Treating Fields Story - Sahm
HC Wainwright Has Bearish Forecast for NovoCure Q1 Earnings - Defense World
HC Wainwright Has Negative View of NovoCure FY2029 Earnings - MarketBeat
Novocure stock hits 52-week low at $10.66 By Investing.com - Investing.com South Africa
C WorldWide Group Holding A S Grows Position in NovoCure Limited $NVCR - MarketBeat
Novocure stock falls after CMS revokes billing privileges By Investing.com - Investing.com South Africa
Novocure stock falls after CMS revokes billing privileges - Investing.com
NovoCure (NASDAQ:NVCR) Sets New 52-Week LowWhat's Next? - MarketBeat
Novocure stock hits 52-week low at $10.66 - Investing.com
**NovoCure Faces CMS Billing Privileges Revocation** - TradingView
Take Profit: Is NovoCure Limited stock showing strong momentumTrade Volume Report & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Piper Sandler reiterates Overweight rating on NovoCure stock By Investing.com - Investing.com South Africa
Piper Sandler reiterates Overweight rating on NovoCure stock - Investing.com
Hussman Strategic Advisors Inc. Takes $1.09 Million Position in NovoCure Limited $NVCR - MarketBeat
NovoCure Limited (NVCR) Stock Analysis: An Investor’s Look at 81.53% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Emerald Mutual Fund Advisers Trust Has $248,000 Stock Position in NovoCure Limited $NVCR - MarketBeat
NovoCure Limited (NVCR): Investor Outlook on a 76% Potential Upside in Medical Device Innovation - DirectorsTalk Interviews
NovoCure Limited (NASDAQ:NVCR) Short Interest Update - MarketBeat
NovoCure Limited (NASDAQ:NVCR) Receives Average Rating of “Hold” from Analysts - Defense World
NovoCure’s (NVCR) “Neutral” Rating Reaffirmed at Wedbush - Defense World
Assessing NovoCure: Insights From 4 Financial Analysts - Benzinga
NovoCure (NVCR) Rating Reiterated as Neutral by Wedbush | NVCR S - GuruFocus
A Look At NovoCure (NVCR) Valuation After Record 2025 Revenue And CEO Transition - simplywall.st
Novocure Ltd (NVCR) 財務データ
収益
当期純利益
現金流量
EPS
Novocure Ltd (NVCR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Brackmann Christoph | Chief Financial Officer |
Jul 29 '25 |
Buy |
11.59 |
20,000 |
231,800 |
141,150 |
| Stafford Kristin | Director |
Jun 03 '25 |
Sale |
17.28 |
999 |
17,259 |
3,054 |
| LEUNG GABRIEL | Director |
Jun 03 '25 |
Sale |
17.31 |
999 |
17,297 |
81,229 |
| Madden Martin J. | Director |
Jun 03 '25 |
Sale |
17.19 |
999 |
17,176 |
18,674 |
| Scannell Timothy J | Director |
Jun 03 '25 |
Sale |
17.32 |
999 |
17,299 |
6,018 |
| HILLEMAN JERYL L | Director |
Jun 03 '25 |
Sale |
17.26 |
999 |
17,247 |
5,591 |
| Ocean Allyson J | Director |
Jun 03 '25 |
Sale |
17.29 |
999 |
17,269 |
3,054 |
| VERNON W ANTHONY | Director |
Jun 03 '25 |
Sale |
17.35 |
999 |
17,329 |
167,887 |
| Hung David | Director |
Jun 03 '25 |
Sale |
17.30 |
999 |
17,280 |
12,195 |
| Leonard Frank X | EVP, Pres., Novocure Oncology |
Jun 02 '25 |
Sale |
17.50 |
30,196 |
528,413 |
168,452 |
1.47%
0.73%
大文字化:
|
ボリューム (24 時間):